Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2026

Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: Data from a real-world prospective cohort study

RMD Open 2025;11:e006333 Doi: 10.1136/rmdopen-2025-006333

Temiz A,

Temiz et al. showed that this long-term data provides strong evidence that BARI maintains its clinical efficacy, drug survival and acceptable safety profile as monotherapy over several years in a real-world setting. Authors evaluated the long-term efficacy, drug survival and safety of BARI monotherapy versus combination therapy in a prospective cohort of patients with RA.

Keywords:

March 2024

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial

Lancet 2024;403(10429):850–859 doi 10.1016/S0140-6736(23)02650-8

Rech J,

Hagen M,

Braun J,

Kiltz U,

Fleck M,

Voll R,

Thiel J,

Feist E,

Largo R,

This study by Rech, et al. shows that 6-month treatment with abatacept was associated with a decrease in MRI inflammation, clinical symptoms, and risk of RA development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase.

Keywords:

June 2023

Baricitinibe melhora as propriedades ósseas e a biomecânica em pacientes com artrite reumatoide - Resultados do estudo prospectivo intervencional BARE BONE

Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print

Simon D,

Bayat S,

The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.